促肝细胞生长素对原发性肝癌化疗辅助作用观察  

effects with of PHGF on chemotherapeutics of primary hepatocellular carcinoma

作　　者：叶红军[1] 杨春荣[1] 金珍婧[1] 邵建[1] 杨献军[1] 吴恩余[1] 赵孟宇[1] 

机构地区：[1]白求恩医科大学第二临床学院消化科,白求恩医科大学第二临床学院CT科,白求恩医科大学第二临床学院化验科

出　　处：《临床肝胆病杂志》1995年第4期192-194,共3页Journal of Clinical Hepatology

摘　　要：本文对２９例晚期原发性肝癌（ＰＨＣ）病人采用肝动脉门静脉双置泵化疗（置泵组）和静脉化疗（静脉组），用促肝细胞生长素（ＰＨＧＦ）作为辅助治疗。另将单纯化疗患者作为对照。结果表明使用ＰＨＧＦ患者无血细胞减少和肝功能改变等化疗副作用发生，置泵组平均生存期９个月，静脉组平均生存期６．５个月，对照组平均生存期３．６个月。提示ＰＨＧＦ与化疗药物使用，可改善症状，减少化疗副作用，缩小肿瘤，延长生存期。ＰＨＧＦ还可促进外周血单个核细胞（ＰＢＭＣｓ）产生干扰素（ＩＦＮ），增强机体抗肿瘤免疫活性。Abstract patients with primary hepatocellular carcinoma were trested with chemotherapeutics by setting pumps to hepatica propria and portal vein or peripheral vein. These patients were also treated with hepatocyte growth-promoting factor (PHGF). The results showed that the conbination therapy may improve synstoms, such reducing pain and increasing appetice. It may reduce injury of blood cells or hepatic function, and prolong existed time of patients with primary hepatocellular carcinoma. The exist time in patients treated with chemotherapeutics and PHGF by setting pumps means 9 months, it means 6. 5months in patients treated with chemotherapeutics and PHGF by peripheral vein, it means 3. 6 months in patients with chemotherapeutics alone. PHGF therapy stimulate peripheral blood mononuclear cells to produce interferone and inhance anti-cancer immune function.

关 键 词：肝肿瘤 促细胞肝生长素 药物疗法 干扰素 

分 类 号：R735.705[医药卫生—肿瘤] R730.53[医药卫生—临床医学]